Latest Oncology News

Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

September 19th 2021

Kyle Doherty

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

September 19th 2021

Gina Mauro

The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.

Tisotumab Vedotin Plus Frontline Carboplatin and Second-/Third-Line Pembrolizumab Demonstrates Notable Activity in Recurrent/Metastatic Cervical Cancer

Tisotumab Vedotin Plus Frontline Carboplatin and Second-/Third-Line Pembrolizumab Demonstrates Notable Activity in Recurrent/Metastatic Cervical Cancer

September 19th 2021

Caroline Seymour

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

September 19th 2021

Conor Killmurray

Adagrasib alone or in combination with cetuximab elicited encouraging antitumor activity and safety in heavily pretreated patients with KRAS G12C–mutant colorectal cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.

Survival Benefit Found With Abiraterone/Prednisolone-Based Combos in High-Risk Nonmetastatic Prostate Cancer

Survival Benefit Found With Abiraterone/Prednisolone-Based Combos in High-Risk Nonmetastatic Prostate Cancer

September 19th 2021

Matthew Fowler

When added to androgen-deprivation therapy, abiraterone acetate and prednisolone with or without enzalutamide for 2 years improved survival outcomes in men with high-risk nonmetastatic prostate cancer.

Latest Oncology Videos

All Oncology News

Prednisone Added to ADT Plus Docetaxel Improves Radiographic PFS and OS in mCSPC

September 19th 2021

Jamie Cesanek

Prednisone added to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.

Novel Therapy Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

September 19th 2021

Colleen Moretti

Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.

Nivolumab-Rucaparib Combo Induces Clinically Effective Outcomes in Subgroup of Patients with mCRPC

September 19th 2021

Ryan McDonald

A group of patients with metastatic castration resistant prostate cancer achieved favorable outcomes after receiving treatment with nivolumab in combination with rucaparib.

Switch to Darolutamide Maintenance Improves Survival in Taxane and NHA Pretreated mCRPC

September 19th 2021

Nichole Tucker

Switching maintenance to darolutamide following taxane-based therapy with at least 1 novel hormonal agent showed statistically significant but clinically modest improvement in radiographic progression-free survival and event-free survival in patents with metastatic castration-resistant prostate cancer.

Ribociclib/Letrozole Combo Yields Significant OS Benefit in Postmenopausal HR+/HER2- Advanced Breast Cancer

September 19th 2021

Courtney Marabella

The combination of ribociclib and letrozole demonstrated a statistically significant and clinically meaningful overall survival benefit compared with letrozole alone in the first-line setting for postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results from the phase 3 MONALEESA-2 trial.

ctDNA a Viable Surrogate for OS in Previously Treated Metastatic Uveal Melanoma

September 19th 2021

Jason Harris

Circulating tumor DNA was a better predictor for survival than RECIST 1.1 for patients with previously treated, HLA-A*02:01-positive metastatic uveal melanoma assigned to tebentafusp.

Datopotamab Deruxtecan May Lead to Antitumor Activity in Advanced NSCLC With Genomic Alterations

September 19th 2021

Darlene Dobkowski, MA

The antibody drug conjugate datopotamab deruxtecan demonstrated safe antitumor activity in patients with advanced/metastatic non-small cell lung cancer with actionable genomic alterations.

Optical Genome Mapping Offers Potential Tool to Assess Genomic Complexity in CLL

September 19th 2021

Jessica Hergert

Optical genome mapping was found to effectively detect most abnormalities defined by standard methods, such as chromosome banding analysis, chromosomal microarrays, and fluorescence in situ hybridization, as well as several additional abnormalities of unknown clinical significance, in patients with chronic lymphocytic leukemia.

Trastuzumab Duocarmazine Shows PFS Benefit in Pretreated, HER2+ Metastatic Breast Cancer

September 19th 2021

Brielle Benyon

Vic-trastuzumab duocarmazine yielded an improved progression-free survival over standard physician’s choice chemotherapy in patients with pretreated HER2-positive locally advanced or metastatic breast cancer.

Atezolizumab Plus Cabozantinib Shows Meaningful Clinical Activity in mCRPC, Including High-Risk Subsets

September 19th 2021

Jason M. Broderick

The phase 1b COSMIC-021 trial showed clinically meaningful activity with cabozantinib plus atezolizumab in patients with locally advanced or metastatic castration-resistant prostate cancer who have been previously treated, including patients with high-risk features.

Trastuzumab Deruxtecan Bests T-DM1 in First Head-to-Head Study for HER2+ Breast Cancer

September 18th 2021

Jackie Collins

Fam-trastuzumab deruxtecan-nxki demonstrated a clinically meaningful and statistically significant improvement in progression-free survival vs standard of care trastuzumab emtansine for patients with previously treated HER2-positive metastatic breast cancer.

cfDNA-Based MRD Assessment Is Feasible, Yields Highly Concordant Results in Relapsed/Refractory CLL

September 18th 2021

Gina Mauro

The use of a cell-free DNA–based minimal residual disease assay demonstrated feasibility and highly concordant results compared with 4-color flow cytometry and improved MRD detection in patients with chronic lymphocytic leukemia who were treated with time-limited venetoclax, acalabrutinib, and obinutuzumab.

Pembrolizumab/Chemo With or Without Bevacizumab May Represent New Frontline SOC in Cervical Cancer

September 18th 2021

Kristi Rosa

The addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improved survival and response rates in patients with persistent, recurrent, or metastatic cervical cancer.

Adjuvant Pembrolizumab Induces RFS Benefit in Resected High-Risk Stage II Melanoma

September 18th 2021

Jessica Hergert

Adjuvant pembrolizumab led to a significant reduction in the risk of disease recurrence or death compared with placebo in patients with resected, high-risk stage II melanoma.

Pembrolizumab/Olaparib Combo May Improve PSA Response Regardless of HRR Mutation Status in mCRPC

September 18th 2021

Benjamin Saylor

Pembrolizumab plus olaparib may improve prostate-specific antigen response rate in patients with metastatic castration-resistant prostate cancer regardless of homologous recombination repair mutation status.

See All News